Course InformationTherapautic Area: Neurology
Format(s): Post Conference Review and Analysis
Credit(s): 1.0 AMA PRA Category 1 Credit(s)™
Activity Dates: June 12, 2017 – June 11, 2018
This CME program will highlight recent scientific advances in the management and treatment of patients with relapsing multiple sclerosis presented at the American Academy of Neurology 2017 Annual Meeting in Boston, Massachusetts. The three expert faculty will discuss new and emerging therapeutic advances in the treatment of patients with relapsing multiple sclerosis. The most up-to-date clinical trial data will be reviewed and analyzed to better improve outcomes. The faculty will also examine unmet needs and action needed to be taken in order to close the learning gap. Upon completion of this activity, physicians will gain a better understanding of new treatment options and patient management to improve outcomes for patients with relapsing multiple sclerosis.
Neurologists, primary care physicians and other healthcare professionals responsible for the management of patients with MS
- Review diagnostic criteria and prognosis of multiple sclerosis, including the role of immune-inflammation in relapsing disease.
- Analyze clinical trial data of emerging receptor modulator therapeutics for the treatment of relapsing multiple sclerosis presented at AAN 2017.
- Apply recent science into individualized treatment plans to improve outcomes for patients with relapsing multiple sclerosis.
Amit Bar-Or, MD
Melissa and Paul Anderson President’s Distinguished Professor
Director, Center for Neuroinflammation and Neurotherapeutics
Chief, Multiple Sclerosis Division, Department of Neurology
Perelman School of Medicine, University of Pennsylvania
Adjunct Professor of Neurology, Montreal
Neurological Institute, McGill University
Disclosures of Conflict of Interest
It is the policy of AcademicCME that all faculty, instructors, and planners disclose real or apparent conflicts of interest relating to the topics of this educational activity.
The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:
|Faculty||Relationship Identified With:|
|Clyde Markowitz, MD||Consultant/Advisor: Bayer AG; Biogen; EMD Serono, Inc.; Genentech, Inc.; Genzyme Corporation; Novartis Pharmaceuticals Corporation; Opexa Therapeutics, Inc.; F. Hoffmann-La Roche Ltd and Teva Pharmaceutical Industries Ltd.|
|Edward Fox, MD||Consultant/Advisor: Acorda Therapeutics; Bayer AG; Biogen; Chugai Pharamceutical Co.; EMD Serono, Inc.; Genentech Roche; Genzyme Corporation; Novartis Pharmaceuticals Corporation; Teva Pharmaceutical Industries Ltd.; TG Therapeutics|
|Amit Bar-Or||Consultant/Advisor: Biogen; Celgene/Receptos, Inc; DioGenix, Inc; GlaxoSmithKline Pharmaceutical Company; Mediumme; Merck/EMD Serono; Novartis Pharmaceutical Company; Ono Pharmaceutical Co., LTD.; Roche/Genentech; Sanofi-Genzyme and Teva Pharmaceutical Industries Ltd.|
Planners, Managers, Reviewers
Timothy Hayes, MD, PhD; Emma Gilmartin; and Megan Gentile hereby state that they or their spouse/life partner do not have any financial relationships to products or devices with any commercial interests related to the content of this activity of any amount during the past 12 months.
AcademicCME is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Credit Designation Statement
AcademicCME designates this enduring material for a maximum of 1.00 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
This activity has been supported by an independent educational grant from Celgene Corporation.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. AcademicCME and Celgene Corporation do not recommend the use of any agent outside of the labeled indications.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Method of Participation
In order to claim credit, participants must complete the following:
- Read the learning objectives, accreditation information and faculty disclosures at the beginning of this activity.
- Complete the Pre-Activity Questions
- Read or Review the activity content.
- Complete the Post-Activity Test Questions and Evaluation.
- Physicians who receive a grade of 70% or better on the Post-Activity Test Questions and who complete the Evaluation will receive a CME Certificate.
- All other participants who receive a grade of 70% or better on the Post-Activity Test Questions and who complete the Evaluation will receive a Certificate of Participation.
CME Inquiries/Special Needs
Provided by AcademicCME.